Novo Nordisk A/S (NVO)

NYSE (ADR) / Copenhagen · Bagsværd, Denmark · Founded 1923 · CEO Mike Doustdar

Valuation summary

$40.86 fair value versus $38.87 in the market, a difference of +5.1%. Rated Hold.

Fair value per share$40.86
Current share price$38.87
Upside / downside+5.1%
Bear case$28.25
Bull case$58.40
Discount rate (WACC)9.7%
Terminal growth2.80%
Market capitalisation$172B
EV / Sales4.1x

About Novo Nordisk A/S

Formed from the 1989 merger of Novo Terapeutisk Laboratorium and Nordisk Insulinlaboratorium, both founded in the early 1920s to produce insulin in Denmark. Headquartered in Bagsværd and controlled by the Novo Nordisk Foundation; since September 2026 it operates under the single brand name Novo, while the legal entity remains Novo Nordisk A/S. Mike Doustdar became CEO in 2025. Products: Ozempic and Rybelsus for type 2 diabetes, Wegovy for obesity — all semaglutide — plus a large insulin portfolio and rare disease treatments in haemophilia. Novo lost significant ground to Lilly through 2025 and 2026 as tirzepatide outperformed semaglutide on weight loss.

Investment case

  • Semaglutide remains an enormous global franchise with brand recognition that no competitor has matched.
  • Massive manufacturing investment in Denmark and North Carolina secures supply for the next decade.
  • The stock has de-rated so far that expectations are now genuinely low relative to the installed patient base.

Key risks

  • Lilly's tirzepatide has consistently beaten semaglutide on weight loss in head-to-head data, and prescribers have noticed.
  • Earlier CagriSema results disappointed against the bar the company had set, and its September 2026 head-to-head win was against only the 5 mg dose of tirzepatide, so the competitive case is not settled.
  • Semaglutide patent expiry in Canada and other markets arrives sooner than in the US, opening generic entry.

Recent developments

Revenue by segment

Diabetes care52%
Obesity care40%
Rare disease8%

Five-year forecast

RevenueFree cash flow
Year 1$46.5B$12.0B
Year 2$49.1B$12.4B
Year 3$51.8B$12.7B
Year 4$54.7B$13.1B
Year 5$57.8B$13.4B

What the street says

A classic fallen-quality debate. Bulls point to CagriSema beating tirzepatide on weight loss in the REIMAGINE 5 trial in September 2026, with an FDA decision expected in Q4 2026; bears note the shares still fell 7.91% on Capital Markets Day the same day, when management guided only to 2026-2030 revenue growth in line with industry peers.

Comparable companies: GILD · DHR · NVS · AMGN · VRTX · ABT · PFE · TMO

Open the interactive model, price chart and sensitivity grid →